Fig 1: Angio‐3 suppresses FXa‐mediated fibroblast migration and invasion. (A) Representative images of migration assay in pMLFs treated with TGF‐β1 (5 ng/mL), FXa (10 nmol/L) or Angio‐3 (10 μmol/L) for 24 h (scale bars, 50 μm). (B–C) Quantitative analysis of migrated cells under different treatment conditions (n = 5). (D) Representative images of invasion assays in pMLFs treated with TGF‐β1 (5 ng/mL), FXa (10 nmol/L) or Angio‐3 (10 μmol/L) for 24 h (scale bars, 50 μm). (E–F) Statistical analysis of invasive cells in different groups as indicated (n = 5). Data are presented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
Fig 2: Angio‐3 inhibited FXa‐PAR‐1 signaling‐driven fibroblast activation and fibrogenesis. (A) Immunoblot analysis of α‐SMA, collagen I, fibronectin and PAR‐1 expression in pMLFs treated with FXa (10 nmol/L) or Angio‐3 (10 μmol/L) for 48 h. (B–E) Densitometric quantification of α‐SMA (B), collagen I (C), fibronectin (D) and PAR‐1 (E) expression shown in (A). (F) Immunoblot analysis of α‐SMA, collagen I, fibronectin and PAR‐1 expression in pMLFs treated with TGF‐β1 (5 ng/mL), FXa (10 nmol/L) or Angio‐3 (10 μmol/L) for 48 h. (G–J) Quantitative analysis of α‐SMA (G), collagen I (H), fibronectin (I) and PAR‐1 (J) expression. Data are presented as mean ± SD (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
Supplier Page from Fine Biotech Co., Ltd. for Mouse FX (Coagulation factor X) QuickTest ELISA Kit